All human herpesviruses can remain latent, but it is not yet fully understood how latent infection is controlled and why reactivation occurs. This meeting improved our knowledge of this control by examining the immunobiology of four very common human herpesviruses: herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV). Studies of immune control have important implications for the development of herpesvirus vaccines. Live herpesvirus vaccines are undesirable because of the risk of latency and oncogenicity. DNA-free synthetic vaccines have therefore been advocated; a subunit EBV vaccine has recently been shown to protect cottontop tamarins from the effects of a tumour-inducing dose of EBV1.
It became apparent at this meeting that, since cell-mediated immunity (CMI) plays an essential role in the control of herpesvirus infection, successful synthetic vaccines must stimulate CMI as well as humoral immunity. Viral antigens which are targets for humoral immunity have been studied in detail for diagnostic purposes and also to assess their potential as vaccines. Less is known about the target antigens for CMI. At this meeting we heard that viral antigens or virus-induced changes produced at the cell surface early in the course of infection by such viruses as EBV, CMV and mouse CMV, are recognized by both cytotoxic T lymphocytes (CTL) and natural killer (NK) cells.
Herpesvirus infections are generally more severe in immunocompromised patients owing to reduced CMI, and effective vaccines are especially needed to protect these patients. Until such vaccines are available, specific antiviral drugs are required to control life-threatening infections. Acyclovir and ARA-A (vidarabine) are effective against HSV and VZV. Such drugs as BW759U and Foscarnet, which have been developed more recently, may be effective against CMV. The development of effective treatment increases the need for early viral diagnosis. Immunochemical methods are now available for the rapid diagnosis of HSV and CMV. Such methods are likely to be used more often in the future.
Possible sites of latency of the different herpesviruses is another area of current interest. Although HSV and VZV are known to remain latent in nerve ganglia, the sites for CMV and EBV are unknown. Indeed, these latter viruses may persist by chronic low-grade infection rather than by latent infection. In this context there is thought to be a reservoir of EBV persistence in the oropharynx, possibly in specialized epithelial cells. Possible cells where CMV may persist are renal epithelium, salivary gland epithelium, macrophages and lymphocytes.
Immunological responses to the herpesviruses have been studied in some detail in relative ignorance of their molecular biology. Dr J Barklie Clements (Institute of Virology, Glasgow) therefore began the meeting with a comparison ofthe molecular biology of the herpesviruses.
All herpesviruses have a large genome consisting of double-stranded DNA, with molecular weights ranging from 80 to 150 megadaltons. Sequencing of viral DNA has revealed differences in the DNA composition and organization of the herpesviruses. While the DNA of HSV types 1 and 2 is 50% homologous, the HSV and VZV genomes have only eight regions of good homology in the S genome segment2. These conserved regions are probably essential for virus function and might be suitable targets for antiviral action, while non-conserved variable length regions may be of less importance.
These large viral genomes can code for many proteins. HSV has 30-36 different structural proteins and more virus specified polypeptides are found in infected cells. HSV has a carefully regulated scheme for gene expression and polypeptide production. There are five or six immediate early (IE) genes coding for IE proteins, which are phosphorylated, accumulate in the nucleus and have DNA binding properties in vitro. One of the IE proteins (mol wt 175 000 in HSV1) is essential for virus replication as it is responsible for switching on both early and late genes3. Another structural protein (mol wt 65 000) is required to switch on the IE genes to full production, a process known as transactivation4. This protein acts on certain HSV DNA sequences, which are recognized as activator sequences5. Both the 175 000 and 65 000 regulatory proteins are potential targets for the action of antivirals. Hormones may influence activation, and this may help to explain why recurrence is sometimes related to the menstrual cycle.
Dr Clements suggested that other potential targets for antivirals are virus-induced enzymes. It might be possible to prevent virus replication by blocking the production and activity of enzymes such as alkaline exonuclease, thymidine kinase, DNA polymerase and ribonucleotide reductase. Viral DNA polymerase is an important enzyme as it is responsible for the production of new virus DNA. Acycloguanosine (Acyclovir), which has been shown to be effective against HSV and VZV, is converted by the viral thymidine kinase to acycloguanosine triphosphate, which then interferes with the action of the viral DNA polymerase.
The viral glycoproteins present in the viral envelope are expressed at the cell surface and are thus thought to be the targets for immune attack. The major glycoproteins B, C and D map in the same region of the HSV1 and HSV2 genomes6. There are type-specific and type-common domains in these regions. Glycoprotein D (gD) of HSV is accepted Report of meeting of Section of Clinical Immunology & Allergy, 11 February 1985 0141-0768/86/ 090550-05/$02.00/0 o 1986 The Royal Society of Medicine as the major antigenic determinant. VZV has no equivalent to gD, but it possesses a DNA region coding for gE (Fc receptor) homologous with HSV2. The presence of these homologous regions may explain why infection with HSV and VZV can stimulate antibodies to the heterologous virus. The product of a DNA region in one virus might induce an immune response which would protect against other viruses with the same DNA sequence. Thus, the gD of HSV1 and HSV2 can protect mice against lethal infection with either virus. A subunit HSV vaccine might also protect against VZV.
Dr A A Nash (Department of Pathology, University of Cambrige) spoke about the immunology of herpes simplex virus infection. His group has been using two mouse models to study the immune response and the mechanism of latency. The first is a model for primary and latent infection, in which the mouse ear is infected with HSV7. Following inoculation, virus replicates in the epidermis, enters the nerve endings and then travels by way of the nerve axons to the sensory ganglia. It can pass up and down again throughout primary infection to infect multiple sites on the epidermis. Following primary infection, virus remains latent in the neurones of the ganglia and probably in the central nervous system. As in man, a neutralizing antibody response persists throughout the life of the mouse. Delayed hypersensitivity peaks at about day eight, and also remains inducible for life. Dr Nash and his colleagues used immunodeficient mice to show that T-cell immunity is important for the control of primary infection, since B-cell-deficient mice responded normally, but T-cell-deficient mice died of an overwhelming CNS infection8. By sampling cells from the draining lymph nodes of infected mice and transferring them to normal mice, they showed that T-helper cells play a major role in the control of primary infection, whereas cytotoxic T-cells are less important. Using an HSV-specific T-cell clone of the helper phenotype, restricted by class II MHC antigens, they have shown that helper T-cells mediate protection by producing a macrophage-activating factor (probably y interferon)9. The activated macrophages can kill HSV-infected target cells directly or indirectly by secreting arginase, which depletes the local arginine, essential for HSV replication'0.
To study recrudescence, Dr Nash and his colleagues have used a 'zosteriform' mouse model. The mouse is initially infected on a scarified region of the flank and 5-6 days later a 'zosteriform' reaction appears on the lower flank". Virus can be recovered from the inoculation site and from the new lesion on the lower flank. If immune cells are inoculated within 24 hours of primary infection, before ganglionic infection has been established, virus can be eliminated from the inoculation site. It was also shown that the zosteriform rash can be prevented by giving high-titre neutralizing antibodies within 60 hours of infection. Antibody therapy might therefore have a beneficial effect on HSV infections'2. Histology has shown that even three days after inoculation there is no cellular infiltration at the secondary site, suggesting that the virus present in the epidermis is temporarily inaccessible to the immune response. An inflammatory response occurs only when there has been sufficient viral cytolysis to cause breakdown of the epidermal basement membrane and the appearance of a rash". A similar situation may exist in man. When a recrudescence (e.g. cold sore) occurs, only the epidermal cells are infected initially, and there is therefore a delay in immune control.
Dr Nash also discussed prospects for an HSV vaccine. Current work on developing genetically engineered vaccines has concentrated on the major antigenic determinant, glycoprotein D. Three types of vaccine are under development: HSV mutants which are latency negative, purified glycoproteins expressed in eukaryotic cells'", and HSV-vaccinia recombinants'4. The latter two vaccines have been shown to protect mice against lethal challenge. Dr Nash suggested that antibody induced by such vaccines would prevent bloodborne spread of virus and hence fatal brain infection, but might not prevent mucosal infection, for which cell-mediated immunity is necessary. There is also a demand for vaccines that will modify recurrent disease, for which it may be necessary to stimulate better humoral and cellmediated immune responses to certain HSV glycoproteins. Perhaps HSV vaccines should be tested in the mouse models Dr Nash described.
Professor A B Rickinson (Department of Cancer Studies, University of Birmingham) discussed interactions of EBV with the immune system. EBV is widespread, causing asymptomatic infection in childhood, but infectious mononucleosis in about half the persons infected in adolescence or later. EBV induces a lifelong carrier state; periodic reactivation occurs when virus can be recovered from throat washings. Because of the lack of a lytic cycle in vitro and of suitable animal models, most studies on the immunobiology of this virus have been conducted with human lymphocytes. Studies on EBV infection of human B lymphocytes have shown that the first antigens to be induced are the nuclear antigen (EBNA) and the lymphocyte-detected membrane antigen (LYDMA). Cellular DNA synthesis then occurs, leading to immunoglobulin production and cell proliferation. This cell proliferation can be controlled by virus-specific cytotoxic T-cells. In vitro, T-cells from seropositive donors will kill EBVtransformed B-lymphoctyes and prevent the outgrowth of these cells'5. This T-cell-mediated killing is restricted by class I HLA antigens and does not occur if T-and B-lymphocytes are completely mismatched at the HLA-A and B loci.
As for HSV, little is known about the viral antigens recognized by T-cells. Professor Rickinson reminded the audience that although one might expect a membrane protein to be the target, an intracellular viral nucleoprotein induced by influenza A is the principal target for cytotoxic T-cells in this viral system; one must look for any gene product that might be expressed on the cell surface.
For EBV, there must be a reservoir of infection, which produces low levels of virus continuously. Evidence for such a persistent infection includes (1) the continual shedding of infectious virus from the throat by the majority of seropositive persons; (2) spontaneous transformation of lymphocytes from seropositive persons in vitro; and (3) stable levels of specific antibodies and virus-specific memory T-cells. It is thought that the reservoir of infection must be in the oropharynx, perhaps a specialized epithelial cell in the parotid gland or tonsillar crypts. Such a site might be exposed to continual lymphocyte traffic, allowing intimate lymphocyteepithelial cell connections and the passage of EBV into B-cells'6.
Professor Rickinson's group have shown that although the levels of virus excretion and antibody are stable for a given subject, variations occur between individuals. When sensitive assays were used, 25% of subjects were shown to secrete virus in the throat continuously (high secretors), another 60% secreted lower levels of virus on most occasions of testing, while in other individuals virus shedding could never be detected. High secretors were shown to have a relatively high proportion of infected Bcells, yet their antibody levels were not necessarily elevated.
Immunosuppressed organ transplant patients are particularly prone to reactivations of HSV, VZV and CMV. Defective T-cell control of EBV is also suggested by the increased frequency of B-cell lymphomas, in many cases EBV genome-positive, in these patients. Such patients show a higher incidence of virus shedding than normal controls, have increased numbers of infected B-cells in the blood and higher antibody levels than healthy virus carriers; memory T-cell function, however, is depressed. Virus-host balance in these patients is currently under investigation.
The cellular events associated with EBV infection have recently been reviewed'6.
Dr L K Borysiewicz (Department of Medicine, Royal Postgraduate Medical School) spoke briefly about immunity to VZV before describing his studies with Dr Patrick Sissons on immunity to CMV. Although VZV is responsible for considerable morbidity, our knowledge of immunity to this virus is very limited because of the difficulty of growing the virus in cell culture and its strong species specificity. Antibodies can be measured by a variety of techniques but it is generally accepted that it is the antibodies to membrane antigens of infected cells, measured by a fluorescent antibody technique (FAMA), which are associated with protection. Antibodies are known to prevent primary infection since passive immunization with zoster immune globulin (ZIG) is effective. CMI is considered to be more important for the control of latent infection; reactivation in the form of zoster occurs when CMI responses have declined, usually in old age. Further studies are currently in progress, stimulated by the success of the attenuated varicella vaccine (OKA strain), since it is recognized that a successful vaccine must induce both humoral and CMI '7 responses CMV infections are most frequently asymptomatic but can cause considerable morbidity, particularly among organ transplant patients, in whom primary infection or reactivation may have serious consequences. If acquired in pregnancy, CMV can cause intrauterine infection, and sometimes congenital malformations'8. Latent infection is common, but the site of latency is unknown. CMV induces a wide range of antibodies, but virus reactivation is thought to be limited by CMI and is most likely to occur when CMI is depressed by disease or immunosuppressants. In order to determine which CMI responses are important for control of infection, Dr CTL responses were measured using a panel of HLA typed human fibroblast cell lines infected with CMV and expressing IEA, early antigens (EA) and late antigens (LA). When PBL from seropositive donors were co-cultivated with these cells, CTL killing, as measured by a 5"Cr-release assay, was shown to be virus-specific and restricted by class I MHC antigens. The T-cells recognized EA and this response may therefore be important for the early control of infection"9. It has been shown in bone marrow transplant patients with active CMV infection that those patients with the lowest CMVspecific CTL responses were most likely to die20. A CTL response to IEA has also been demonstrated for mouse cytomegalovirus.
Dr Borysiewicz suggested that the NK response may limit CMV reactivation in normal latently infected individuals, since CMV-infected target cells expressing EA but not LA have been shown to be susceptible to NK cell killing. The target for NK cells was also present, however, on uninfected cells, suggesting that the target structure recognized by NK cells was probably not coded by the virus. Interestingly enough, CMV-EA expression and susceptibility to NK lysis correlated with enhanced transferrin receptor expression". Dr Borysiewicz also mentioned some very recent results which suggest that CMV itself can suppress immune responses, by producing a protein which can suppress production of interleukin-1, a macrophage activating factor22.
Dr Paul Griffiths (Department of Microbiology, Royal Free Hospital, London) discussed current preventive and therapeutic measures against herpesvirus infections in clinical practice. He re-emphasized that CMI, rather than humoral immunity, is important for control of herpesvirus infections, and suggested that the presence of antibody can be taken as a marker of latent infection and infectivity. CMV seropositive blood should not be given to premature babies or immunosuppressed patients because of the potential risk of transmitting virus. High HSV antibody levels have been shown in some instances to be a marker of increased infectivity23, and high CMV-specific IgM levels are seen in symptomatic congenitally infected infants24. It is of interest that Henle and Henle25 have shown that high antibody levels may be a marker of depressed T-cell activity.
Patients most at risk of herpesvirus disease are those with leukaemia/lymphoma, organ transplants, AIDS, the elderly and neonates ( Table 1 ). In these patients, severe disease may result from primary infection (e.g. neonatal herpes, neonatal varicella, and infections in adults), from reactivation (e.g. HSV, CMV and VZV in immunosuppressed patients), or from reinfection (e.g. CMV in immunosuppressed patients, HSV in AIDS patients). Three possible strategies for the prevention of infection and disease were proposed: prevention of transmission, immunization of the host, and prophylactic treatment. Examples ofprophylactic treatment are the use of acyclovir after organ transplantation, and zoster immune globulin after exposure of a seronegative leukaemic to varicella. The attenuated varicella vaccine, OKA strain, the only licensed human herpesvirus vaccine, has been successfully used to protect leukaemic children' 7, although live vaccines are usually contraindicated in such patients. Trials of this vaccine are considered justified since the consequences of infection are more serious than the possible consequences of vaccination. Use of a CMV vaccine in organ transplant patients is also justified, but trials with the Towne strain attenuated vaccine has been disappointing.
Although the trend is to prevent infection, many patients are only treated once infection has occurred. Thus, acyclovir is used to treat herpes encephalitis and neonatal herpes, and ARA-A, and acyclovir can be used to treat varicella/zoster26'27.
CMV-immune globulin is apparently successfully being used to treat CMV infections in immunocompromised patients28 and it is hoped that derivatives of acyclovir, such as BW759U, may also be effective against this virus.
Dr Griffiths pointed out that an early virological diagnosis is essential for successful treatment and effective trials of antiviral agents. A clinical diagnosis may sometimes be possible, as in the cases of chickenpox and zoster, but virus identification is the method of choice in immunocompromised patients. Isolation of virus in cell culture takes too long to be useful for the rapid diagnosis of VZV, CMV and EBV infections. Although electron microscopy may be useful for detecting virus in skin lesions, Dr Griffiths recommended immunochemical methods for the rapid identification of other infections. As an example he described the rapid diagnosis (27 hours) of CMV infection using a fluorescein-labelled monoclonal antibody to EA29. He suggested that a similar technique could be applied to VZV. Monoclonal antibodies are also available for the rapid diagnosis of HSV infections30.
Jennifer M Best In her paper on 'The history of ultrasonography in obstetrics', she traced the use of ultrasound from its development as a submarine detection method during the First World War, through its use in the mid-1950s as a device for the detection of abdominal tumours (many of which were found to be pregnancies), to the late 1960s when its use was extended, firstly to the measurement of fetal biparietal diameter and the diagnosis of blighted ova, and later to the routine estimation, in many hospitals, of fetal growth and maturity. She noted that all this had taken place despite the lack of controlled trials to determine the safety and efficacy of the technique, and that in addition its use encouraged the substitution of 'objective' data for the 'patient-generated' data of before, a process during which the social relationship between patient and caregiver was likely to be diminished. In the discussion which followed concern was expressed that the combination of media-generated consumer demand and the readiness ofsome members of the medical profession to use new technological procedures before they had been properly evaluated, had resulted in the use of ultrasound for a large proportion ofpregnant women. Once ultrasound became the 'norm' its use rapidly became synonymous with good care, regardless of its actual value. Since its use was painless to the pregnant woman and indeed might appear to her to have advantages, it was less likely to be questioned than, for example, induction. The combination of all those factors put the more cautious professionals in the position of having to explain, to both their colleagues and the women in their care, why they were not using the technique.
Indications
The second speaker was Dr James Neilson (Queen Mother's Hospital, Glasgow) who examined in his paper the 'Indications for ultrasonography in obstetrics'. He felt that ultrasound was useful at amniocentesis, and to identify twins. It could also establish gestational age in early pregnancy, fetal anomalies and death. A study in his hospital of late pregnancy ultrasound screening, in which the product ofcrownrump length and trunk area was calculated, was highly effective in predicting small-for-dates babies but was unable to demonstrate any benefit in either management or outcome.
He noted that the National Institutes of Health Consensus Task Force on Ultrasound in Pregnancy and the comparable British body, the Royal College of Obstetricians and Gynaecologists working party, had come to opposite conclusions on the value of early pregnancy screening after analysis of similar data.
With regard to late pregnancy screening, four randomized controlled trials of its routine use had so far been conducted. Three had failed to show any benefit while the fourth may have shown decreased mortality but the results had yet to be reported in full.
The following discussion was for the most part critical of routine early pregnancy screening. The suggestion put forward that the 'need' for an early scan might not be apparent until late pregnancy, at which time it would be too late, was countered by drawing attention to the fact that the accuracy of ultrasound in assessing the duration of gestation had not, in general, been validated by reference to pregnancies for which the date of conception was known. It was also felt that reliance on ultrasound undermined the clinical skills that professionals already possessed and would be likely to jeopardize their acquisition by most junior doctors, a fact that had been amply illustrated during the study at Queen Charlotte's Hospital, where 30% ofclinicians were so unsure of their own judgment that they had broken the code to obtain the information provided by ultrasound for women in the control group.
Controlled trials
The next speaker, Dr Adrian Grant (Epidemiologist, National Perinatal Epidemiology Unit, Oxford), reviewed the existing 'Controlled trials of routine ultrasound in pregnancy'. The five trials he analysed were difficult to aggregate as they had differed in their inclusion criteria, outcome variables and trial reporting. He did not feel, however, that they formed 0141-0768/86/ 090554-03/$02.00/0 01986 The Royal Society of Medicine
